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ABSTRACT 
Objectives. Osteophytes are highly prevalent in osteoarthritis (OA) and are associated with pain and 
functional disability. These pathological outgrowths of cartilage and bone typically form at the 
junction of articular cartilage, periosteum and synovium. The aim of this study was to identify the 
cells forming osteophytes in OA. 
Methods. Fluorescent genetic cell-labelling and tracing mouse models were induced with tamoxifen 
to switch on reporter expression, as appropriate, followed by surgery to induce destabilization of the 
medial meniscus (DMM). Contributions of fluorescently labelled cells to osteophytes after 2 or 8 
weeks, and their molecular identity, were analysed by histology, immunofluorescence staining, and 
in situ hybridisation. Pdgfrα-H2BGFP mice and Pdgfrα-CreER mice crossed with multi-colour Confetti 
reporter mice were used for identification and clonal tracing of mesenchymal progenitors. Mice 
carrying Col2-CreER, Nes-CreER, LepR-Cre, Grem1-CreER, Gdf5-Cre, Sox9-CreER or Prg4-CreER were 
crossed with tdTomato reporter mice to lineage-trace chondrocytes and stem/progenitor cell sub-
populations.  
Results. Articular chondrocytes or skeletal stem cells identified by Nes, LepR, or Grem1 expression 
did not give rise to osteophytes. Instead, osteophytes derived from Pdgfrα-expressing 
stem/progenitor cells in periosteum and synovium that are descendants from the Gdf5-expressing 
embryonic joint interzone. Further, we show that Sox9-expressing progenitors in periosteum 
supplied hybrid skeletal cells to the early osteophyte, while Prg4-expressing progenitors from 
synovial lining contributed to cartilage capping the osteophyte, but not to bone. 
Conclusion. Our findings reveal distinct periosteal and synovial skeletal progenitors that cooperate 
to form osteophytes in OA. These cell populations could be targeted in disease modification for 
treatment of OA. 
Keywords: Osteoarthritis, osteophytes, stem cells, synovium, periosteum 
3 
 
 
INTRODUCTION 
A characteristic feature of osteoarthritis (OA) is the formation of osteophytes, which are osteo-
cartilaginous outgrowths that typically form at the joint margins, in the region where the synovium 
attaches to the edge of the articular cartilage and merges with the periosteum. Osteophytes are 
established through growth of an initial cartilage template that is at least partially replaced with 
bone containing marrow cavities.[1,2] At later stages, the bone is typically covered by a cartilage cap 
that can merge with the articular cartilage.[1,2] Despite their high prevalence, the cell populations 
giving rise to osteophytes in OA remain to be defined. 
Several skeletal stem/progenitor cell (SSC) populations have been identified which vary in their 
ability to form cartilage and bone during skeletal development, maintenance and repair. These 
include perivascular cells marked by expression of Pdgfrα and Sca1, Nestin (Nes), or leptin receptor 
(LepR), and Gremlin-1 (Grem1)-expressing cells.[3–9] In addition, during bone regeneration, Sox9-
expressing progenitors in periosteum initiate cartilage callus formation by giving rise to cells that co-
express  chondrocyte and osteoblast markers.[10,11] Recently, we used a Gdf5-Cre model that is 
active in the embryonic knee joint interzone, but not in the adult normal or OA knee,[12–14] to 
show that Gdf5-lineage descendants include SSCs in the adult with ability to repair a focal cartilage 
defect.[15,16] The adult Gdf5 lineage includes Prg4-expressing progenitors in the superficial zone of 
articular cartilage and synovial lining.[15,17–19] 
Here, we show that osteophytes derive from Pdgfrα-expressing Gdf5-lineage cells. These include 
Sox9-expressing progenitors in periosteum that give rise to hybrid skeletal cells that molecularly 
resemble those observed during bone repair, and Prg4-expressing cells from the synovial lining that 
supply chondrocytes to the outer cartilage layer but do not contribute to bone. Thus, our data define 
the progenitor cell subsets contributing to osteophyte formation in experimental OA. 
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METHODS 
 
Mice 
All animal experimental protocols were approved by the UK Home Office and the Animal Welfare 
and Ethical Review Committees of the University of Aberdeen and University of Cambridge, the 
University of Southern California Institutional Animal Care and Use Committee, the Murdoch 
Children’s Research Institute Animal Ethics Committee, or the Animal Use Committee for University 
Hospital Münster. We used Col2-CreER,[20] Pdgfrα-CreER,[21] Nes-CreER,[22] LepR-Cre,[23] Grem1-
CreER,[9] Gdf5-Cre,[16] Prg4-GFP-CreER,[18] and Sox9-CreER mice,[24] Cre-inducible TdTomato,[25] 
Confetti,[26] and mTmG reporter mice,[27] and Pdgfrα-H2BGFP[28] and Nes-GFP[29] mice (see 
Supplementary Table 1). Wild-type SWR/J mice were used for in situ hybridisation experiments. Mice 
were maintained on a 12:12 light-dark cycle, in a temperature-controlled room, with water and food 
ad libitum. 
 
Tamoxifen administration and surgery 
Administration of tamoxifen, dissolved in corn oil, was optimised for each mouse strain based on 
published studies[9,11,18,30,31] and pilot experiments to achieve efficient labelling of intended 
target cells while minimising impact on animal welfare (see Supplementary Table 2 for details). Adult 
male mice underwent surgical unilateral destabilisation of the medial meniscus (DMM) through 
resection of the medial menisco-tibial ligament,[32] with the contralateral knee serving as 
unoperated or sham-operated control (see Supplementary Table 2 or figure legends for age at 
surgery). Mice were anaesthetised with ketamine (50 mg/kg) and medetomidine (0.67 mg/kg) with 
atipamezole (1 mg/kg) post-operatively, ketamine (90 mg/kg) and xylazine (10 mg/kg), or isoflurane 
with 0.1 mg/kg buprenorphine subcutaneously for analgesia. Proliferating cells were labelled by 
subcutaneous injection of 2 mg bromodeoxyuridine (BrdU) immediately after surgery followed by 1 
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mg/ml BrdU in drinking water for 2 weeks. Mice were euthanised for analysis 1, 2 or 8 weeks after 
surgery. Experimenters were not blinded. 
 
Histology and immunohistochemistry 
Tissues were fixed in 4% paraformaldehyde and decalcified in 4-10% EDTA in PBS or 33% (v/v) formic 
acid with 13.5% (w/v) trisodium citrate dihydrate. Samples were embedded in paraffin or frozen in 
OCT and sectioned. Sections were stained with safranin-O (Sigma), with or without fast green 
(Sigma). Fluorescent proteins were either detected by their native fluorescence in cryosections, or 
via immunofluorescence staining on paraffin sections,[33,34] using antibodies listed in 
Supplementary Table 3. Sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Life 
technologies), Hoechst, or TO-PRO-3 (ThermoFisher). 
 
Imaging 
Images were acquired using a Zeiss Axioscan Z1 slide scanner, Axioskop 40 with Progress XT Core 5 
camera, Axio Imager 2.0 and Axio Observer Z1 with AxioCam MRm and AxioCam Mrc, 710 META 
Laser-Scanning Confocal Microscope, or Nikon AZ100 Microscope with a Nikon Digital sight DS-Fi1 
camera.  Image analysis was performed using ZEN (Zeiss), ImageJ and QuPath softwares.[35] All 
analyses were performed on a minimum of 3 sections per sample. Percentages of labelled cells were 
calculated from the summed cell counts of all sections analysed for each sample, with marrow 
spaces excluded.  
 
RNA In situ hybridisation 
Fluorescence RNA in situ hybridisation was performed on 7-mm paraffin sections as described.[36] 
RNA probes[11] were generated following kit instructions (Sigma-Aldrich: 11277073910 and 
11685619910) and were detected with Anti-Digoxigenin-POD (Sigma-Aldrich: 11207733910) and 
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Anti-Fluorescein-POD (Sigma-Aldrich: 11426346910). For double-fluorescence in situ hybridisation, 
the TSA Cyanine 3 and Fluorescein system from Perkin Elmer was used as directed (NEL753001KT). 
 
Cell isolation and flow cytometry  
Cells were isolated from mouse knees as described,[15] and stained with fixable viability dye 
eFluor780 (eBiosciences, Hatfield, UK) and antibodies listed in Supplementary Table 4. Data were 
acquired on a BD Fortessa flow cytometer and analysed using FlowJo v10 software (Ashland, OR, 
USA). Unstained and single-labelled cells or antibody-labelled CompBeads (BD Biosciences) were 
used to set compensation. Debris and doublets were excluded based on Forward and Side Scatter 
parameters, dead cells were excluded based on viability dye staining, and gates were applied based 
on Fluorescence-Minus-One controls (Supplementary Fig. 1). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism v5. Graphs show data points of individual 
mice, with mean ± 95% confidence interval (CI). N-numbers indicate number of mice.  
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RESULTS 
 
Osteophytes derive from Pdgfrα-expressing progenitors in periosteum and synovium 
In the DMM model of OA in mice, osteophytes form at the joint margins, often merging with the 
articular cartilage, similar to human OA.[1,2] We combined the DMM model with genetic cell-
labelling and tracing models, to unravel the cell populations giving rise to osteophytes. Pdgfrα is 
broadly expressed by mesenchymal stem and progenitor cells. Using Pdgfrα-H2BGFP mice to identify 
and trace Pdgfrα-expressing cells by long-lived GFP expression, we observed GFP+ cells throughout 
synovium and periosteum of the adult knee (Fig. 1a). In parallel, we tested whether pre-existing 
articular chondrocytes contribute to osteophyte using Col2-CreER;ROSA26:loxP-STOP-loxP-TdTomato 
(Tom) mice treated with tamoxifen at 2 weeks of age, when articular chondrocytes still express high 
levels of Col2a1 and are efficiently labelled (Fig. 1b).[30] Two weeks after DMM in tamoxifen-
induced Pdgfrα-H2BGFP;Col2-CreER;Tom mice, GFP+ chondrocytes were present throughout the 
osteophyte and were negative for Tom (Fig. 1c). Furthermore, there was negligible contribution from 
Tom+ pre-existing chondrocytes to mature osteophytes at 8 weeks post-DMM (Fig. 1d). These 
findings indicate that osteophytes do not develop from articular cartilage but derive from Pdgfrα-
expressing stem/progenitor cells.  
Next, we induced adult Pdgfrα-CreER;Confetti mice with tamoxifen to trace individual Pdgfrα-
expressing cells through stochastic expression of membrane-bound CFP, nuclear GFP, cytoplasmic 
YFP, or cytoplasmic RFP. Negligible fluorescence was detected in the absence of tamoxifen. In 
unoperated knees of tamoxifen-induced mice, fluorescently labelled cells were observed in 
periosteum and synovium (Fig. 1e). Consistent with previous studies utilising the R26-Confetti 
reporter,[37,38] GFP was rarely detected and omitted from analysis. Two weeks after DMM, 23.9% 
(95% CI [17.3%, 30.6%], n=4) of cells in the osteophyte were labelled with either CFP, YFP or RFP (Fig. 
1f,g). This may reflect the low sensitivity of the R26-Confetti reporter to Cre-mediated 
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recombination,[17] and aided the identification of distinct clonal cell populations. Intriguingly, 
clusters of identically coloured chondrocytes, likely derived from individual stem/progenitor cells, 
were observed in the deep periosteum at the bone surface, while distinct clusters of chondrocyte-
like and fibroblast-like cells were found in the overlying synovial tissue (Fig. 1f). These data indicate 
that Pdgfrα-expressing stem/progenitor cells clonally expand and give rise to chondrocytes that form 
osteophytes in experimental OA, and suggest a dual contribution from cells in periosteum and 
synovium. 
 
SSCs marked by expression of Nes, LepR, or Grem1 do not give rise to osteophytes 
Since SSC populations marked by expression of Nes, LepR, or Grem1 express Pdgfrα,[3,7–9] we 
investigated whether they contribute to osteophyte formation. Cells marked by Nes-GFP or Nes-
CreER;Tom expression remained confined to vascular niches in synovium, periosteum and bone 
marrow, likely including pericytes and endothelial cells,[8,9,39] with no detectable contribution to 
either cartilage or bone of the osteophyte at 2 or 8 weeks post-DMM (Fig. 2a-c). We next analysed 
LepR-Cre;Tom mice, since LepR-traced cells have been reported to make significant contributions to 
adult bone turnover and repair following fracture.[8] LepR-traced cells were present in synovium and 
periosteum but negligible contribution to osteophytes was observed (Fig. 2d,e). We also used 
Grem1-CreER;Tom mice to trace Grem1-expressing SSCs, as they are distinct from Nes-GFP+ cells and 
contribute to fracture repair.[9] Following tamoxifen induction at 7 weeks of age, we found no 
contribution of Grem1-traced cells to osteophytes at 2 weeks post-DMM (Fig. 2f). These data show 
that Nes-, LepR-, and Grem1-expressing SSCs do not form osteophytes. 
 
Osteophytes arise from adult progeny of the Gdf5-expressing embryonic joint interzone 
Cells in adult knees that are traced from Gdf5-expressing joint interzone cells in the embryo are 
present in synovium and adjacent periosteum (Fig. 3a), and include SSCs.[15] Analysis of cells 
9 
 
isolated from knees of Pdgfrα-H2BGFP;Gdf5-Cre;Tom mice (Fig. 3b) revealed that the vast majority 
of Tom+ Gdf5-lineage cells express Pdgfrα-H2BGFP (93.6%, 95% CI [87.6%, 99.6%], n=9), with Gdf5-
lineage cells constituting approximately one-third of all Pdgfrα-H2BGFP+ cells (Fig. 3c,d). Both 
Pdgfrα-expressing Gdf5-lineage cells (GFP+Tom+) and other Pdgfrα-expressing cells (GFP+Tom-) 
expressed, to varying degrees, the mesenchymal stromal cell and fibroblast markers podoplanin 
(Pdpn/Gp38), CD90, CD73, CD51 and CD105, while neither population included haematopoietic cells 
(CD45+), endothelial cells (CD31+), or erythrocytes (Ter-119+) (Fig. 3e-h, Supplementary Fig. 1). 
These findings indicate that adult Gdf5-lineage cells are a subset of Pdgfrα-expressing cells that may 
form osteophytes. 
We thus induced DMM in Gdf5-Cre;Tom mice, followed by 2 weeks of BrdU administration to label 
proliferating cells. At 2 weeks post-DMM, Gdf5-lineage cells had extensively proliferated and 
expanded (Fig. 4a,b), and they were major contributors to Col2-expressing chondrocytes in the 
osteophytes (Fig. 4b). Tom+ Gdf5-lineage cells constituted 82.5% (95% CI [65.1%, 99.8%], n=4), and 
BrdU+ cells constituted 82.4% (95% CI [69.9%, 94.8%], n=4), of cells within osteophytes at 2 weeks 
post-DMM (Fig. 4c). Tom+ Gdf5-lineage cells remained abundant in mature osteophytes at 8 weeks 
post-DMM (Fig. 4d). They included 87.7% (95% CI [80.0%, 95.4%], n=7) of cells in the cartilage cap 
and 70.8% (95% CI [63.6%, 78.1%], n=7) of osteocytes in the bone (Fig. 4e), as well as bone lining 
cells at endosteal surfaces (Fig. 4d). These data indicate that the Pdgfrα-expressing progenitors that 
form osteophytes are largely contained within the joint-resident Gdf5-lineage population, which 
undergo extensive proliferation to supply cells that form both cartilage and bone. 
 
Sox9-expressing progenitors give rise to hybrid skeletal cells to initiate osteophytes 
Next, we sought to refine which progenitor populations contribute to osteophytes. Clonal tracing of 
Pdgfrα-expressing cells had indicated a possible dual origin from periosteum and synovium (Fig. 1f). 
Sox9-expressing progenitors in adult periosteum supply skeletal cells to the callus during femoral 
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fracture repair and large-scale rib regeneration.[10,11] We therefore performed lineage tracing of 
adult Sox9-expressing cells in experimental OA by treating Sox9-CreER;Tom mice with tamoxifen 
prior to DMM surgery. Mice not treated with tamoxifen showed absence of Tom expression. In 
knees of tamoxifen-treated uninjured mice, Tom+ cells were detected in periosteum (Fig. 5a). At 2 
weeks post-DMM, we observed Tom+ Sox9-traced chondrocytes throughout the early osteophyte 
(Fig. 5b), thus identifying Sox9-expressing progenitors as important contributors of osteophytes. 
During regeneration of the adult mouse rib bone, Sox9-expressing periosteal cells form a callus 
composed of hybrid skeletal cells; these “hybrid” cells are characterised by strong co-expression of 
chondrocyte and osteoblast genes.[11] Similarly, Col2a1-expressing cells in the forming osteophyte 
co-expressed the osteoblast and hypertrophic chondrocyte marker Ocn as early as 1 week post-
DMM (Fig. 5c). In contrast to growth plate chondrocytes, they also co-expressed Col1a1 (Fig. 5c), 
which was particularly apparent in the large osteophytes that typically form on the Col2-CreER 
background (Supplementary Fig. 2). At 2 weeks post-DMM, Col2a1-expressing chondrocytes were 
also positive for the osteoblast and hypertrophic chondrocyte marker Spp1, and the hypertrophic 
chondrocyte marker Col10a1 (Fig. 5d). We confirmed in the Sox9-CreER;Tom model that Sox9-traced 
cells are the source of at least some hybrid cells, based on co-localization of Tom with Col2a1 and 
Col1a1 mRNA expression (Fig. 5e). These findings indicate that the early osteophyte is composed of 
Sox9-derived hybrid skeletal cells similar to those described for rib bone regeneration. 
 
Prg4+ progenitors contribute to cartilage but not to bone in osteophytes 
The Gdf5 lineage includes Prg4-expressing cells in the synovial lining, which expand in response to 
acute focal cartilage injury.[17] We therefore investigated whether Prg4-expressing cells contribute 
to osteophyte formation. We first used Prg4-CreER;ROSA26:loxP-membrane-Tomato-loxP-
membrane-GFP (mTmG) mice induced with tamoxifen at 7 weeks of age. No GFP was detected in 
mice not treated with tamoxifen. At 2 weeks post-DMM, we observed expansion of GFP+ Prg4-
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traced cells in synovium, and Prg4-traced cells were found in the outer region of the early 
osteophyte, while minimal contributions of these cells to the deeper hybrid skeletal cells, expressing 
Col2a1 and Col1a1, was observed (Fig. 6a,b). To confirm these findings and determine the role of 
Prg4-traced cells at later stages of osteophyte formation, we performed similar Prg4-tracing 
experiments using the Cre-inducible Tom reporter model, and extended analysis to 8 weeks post-
DMM (Fig. 6c-h). Osteophytes in Prg4-CreER;Tom mice at 2 weeks post-DMM were typically more 
advanced than those observed in the Prg4-CreER;mTmG model, with a layer of cartilage surrounding 
a hypertrophic centre undergoing remodelling to bone (Fig. 6d). As well as expanding in synovium, 
Tom+ Prg4-traced cells constituted 41.9% (95% CI [27.7%, 56.1%], n=8) of chondrocytes embedded 
in a cartilage matrix immunostaining for Col2 (Fig. 6d,e). Consistent with the data in the Prg4-
CreER;mTmG model (Fig. 6b), they were predominantly found in the outer region, with some 
contribution to Col10-expressing hypertrophic chondrocytes in deeper regions of the osteophyte 
(Fig. 6f). At 8 weeks post-DMM, Tom+ Prg4-traced cells persisted in the cartilage cap covering the 
mature osteophyte but were barely detected in bone (Fig. 6g,h). Thus, Prg4-lineage cells from the 
overlying synovial tissue supply chondrocytes to the forming osteophyte, and while they persist in 
the cartilage cap of the mature osteophyte, they make negligible contributions to bone. 
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DISCUSSION 
Osteophytes are a key feature of OA, and their occurrence is a criterion for imaging-based diagnosis 
of OA.[40] In peripheral joint OA, osteophytes are associated with pain, knee structural progression 
and incidence of joint replacement.[41-43] Nonetheless, research in OA pathogenesis has largely 
focused on mechanisms of articular cartilage breakdown, while the extensive joint remodelling 
events have been considered secondary. Osteophytes, however, are not always linked to severity of 
articular cartilage loss.[44] Understanding the biology of osteophyte formation will provide critical 
insights in the mechanisms underlying the structural derangements that occur in OA joints. 
We show that osteophytes primarily arise from descendants of Gdf5-expressing embryonic joint 
interzone cells that reside in the adult knee. Together with our previous data showing that Gdf5-
lineage cells underpin synovial hyperplasia and cartilage repair after injury,[15] these findings point 
to a central role of Gdf5-lineage cells in the maintenance, repair, and remodelling of adult joint 
tissues. Although osteophytes typically develop close to articular cartilage, Col2a1-expressing 
chondrocytes from articular cartilage did not give rise to osteophytes. Instead, we show that 
osteophytes originate at least in part from a population of Sox9-expressing progenitors in 
periosteum, with progeny of Prg4-expressing synovial-lining cells supplying chondrocytes to the 
cartilage but not osteoblast-lineage cells that form the bone of the osteophyte. 
Several SSC populations have been implicated in bone fracture repair, including SSCs identified by 
expression of Nes, LepR, or Grem1.[4,8,9,45] We observed negligible contribution of these SSC 
populations to osteophytes in OA. Yet intriguingly, our data indicate that the initial stages of 
osteophyte formation are similar to endochondral bone repair in the mouse femur,[10] rib,[11] and 
zebrafish lower jaw.[36] During bone repair, Sox9-expressing cells in periosteum supply 
chondrocytes and osteoblasts, and help to orchestrate callus formation.[10,11] Furthermore, the 
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early callus of the regenerating rib includes Sox9-lineage cells with a hybrid chondrocyte/osteoblast 
identity,[11] similar to what we observed in the early stages of osteophyte formation.  
Until this study, it was not known whether the osteophyte derives from a single progenitor 
population, or whether multiple progenitor populations cooperate to form the different tissue layers 
of the osteophyte. Our data indicate that within the Gdf5-lineage population that forms all parts of 
the osteophyte, periosteal Sox9-expressing progenitors give rise to the deeper hybrid cells that form 
the ossifying cartilage template, while synovial Prg4-expressing cells supply chondrocytes but make 
negligible contributions to osteoblast-lineage cells. Recently, it was shown that joint development 
occurs through a continuous influx of new cells into the Gdf5-expressing joint interzone and flanking 
regions, with cells being temporally specified to contribute differentially to the multiple tissues of 
the joint.[17,46] Our data show that lineage fate determination persists in the adult joint between 
sub-populations of Gdf5-lineage cells and suggest the co-existence of distinct progenitor cell subsets 
with restricted differentiation potential that may have become imprinted through development. 
Human osteophytes in OA hip and knee joints share similar pathological features to those seen in 
mice, with endochondral bone covered by a cartilage cap that merges with or overgrows the 
articular cartilage.[2] Notably, our molecular phenotype data in mouse is consistent with 
observations in human, where an overlap of Col1 and Col2 expression is found in the early stages of 
osteophyte formation, and chondrocytes in the osteophyte express osteocalcin.[2,47] Adult human 
synovium and periosteum are known to contain mesenchymal progenitors,[48,49] which may retain 
the ability to orchestrate an aberrant joint morphogenetic process.[15] Various molecular factors 
and pathways have been implicated in osteophyte formation, including TGFβ and BMP signalling[1]. 
Here, we propose a model whereby joint-resident progenitor cell subsets in periosteum and 
synovium that ontogenetically derive from the embryonic joint interzone respond to such signals 
and cooperate to form osteophytes in OA (Figure 7). Our data define progenitor cell subsets that 
could be targeted as part of disease modification strategies for treatment of OA.  
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FIGURE LEGENDS 
 
Figure 1. Pdgfrα-lineage progenitors, not articular chondrocytes, clonally expand to form 
osteophytes.  
(a) GFP expression (green) by cells in periosteum and synovium of the knee of a 15-week-old mouse 
carrying the Pdgfrα-H2BGFP transgene (n=2). (b) Eight-week-old Col2-CreER;Tom mice induced with 
tamoxifen at 2 weeks of age (n=8, 2 experiments, 7-8 weeks old). Note Tom-labelled cells (red) in 
articular and growth plate cartilage of the knee. (c) Pdgfrα-H2BGFP;Col2-CreER; Tom mice induced 
with tamoxifen at 2 weeks of age and analysed 2 weeks after DMM (n=4, plus n=3 Col2-CreER;Tom 
only). Note Pdgfrα-expressing cells (green) in osteophyte that are negative for Tom (red). (d) Tom 
expression (red) in Col2-CreER;Tom mice induced with tamoxifen at 2 weeks of age and analysed 8 
weeks after DMM (n=6). (e-g) Pdgfrα-CreER;Confetti mice were induced with tamoxifen from 11-12 
weeks of age, followed by DMM surgery and analysis 2 weeks later (n=4). (e) CFP (blue), YFP (yellow) 
and RFP (red) expression in contralateral knee serving as internal control. Arrows indicate labelled 
cells along periosteal surface. (f) CFP (blue), YFP (yellow) and RFP (red) expression in osteophyte of 
destabilised knee. Arrows indicate monochromatic chondrocyte clusters within periosteum, 
arrowheads indicate distinct monochromatic clusters of chondrocyte-like and fibroblast-like cells in 
overlying synovium. (g) Percentage of cells in osteophytes labelled with each of the fluorescent 
proteins, and total percentage of cells labelled (mean ± 95% CI, n=4). Fluorescence microscopy 
images in (a,b,d) show nuclear counterstain in blue. Dashed white lines in (c,d,f) indicate boundary 
between osteophyte and edge of tibia. Brightfield images of near-adjacent sections stained with 
Safranin O and Fast Green are shown on the left in (c-f). A: Articular cartilage, G: Growth plate, PS: 
Periosteum and Synovium junction, S: Synovium. Scale bars in all panels indicate 100 µm.  
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Figure 2. Perivascular and Grem1-expressing skeletal stem cells do not contribute to osteophyte 
formation.  
(a-c) Nes-CreER;Tom mice, some also carrying Nes-GFP, were induced with tamoxifen neonatally. (a) 
Nes-traced cells (red) and Nes-GFP+ cells (green) in knee from 13-week-old unoperated mouse (n=3, 
2 experiments, 6-13 weeks old). (b) Nes-traced cells (red, n=6) and Nes-GFP+ cells (green, n=3) in 
knee 2 weeks post-DMM. Arrows indicate labelled cells around blood vessels in synovium. (c) Nes-
traced cells (red) in knee 8 weeks post-DMM (n=3). Arrows indicate labelled cells associated with 
bone marrow vasculature within osteophyte. (d,e) LepR-Cre;Tom mice underwent DMM surgery at 
12 weeks and were analysed 8 weeks later. (d) LepR-traced cells (red) in uninjured contralateral knee 
serving as internal control (n=3). Arrows indicate labelled cells in synovium and periosteum. (e) 
LepR-traced cells (red) in destabilised knee (n=4). Arrows indicate labelled cells in synovium. (f) 
Grem1-CreER;Tom mice were induced with tamoxifen at 7 weeks of age and left unoperated (n=2) or 
analysed 2 weeks after DMM (n=3). Arrow indicates osteophyte. Fluorescence microscopy images in 
all panels show nuclear counterstain in blue. Dashed white lines in (b,c,e) indicate boundary 
between osteophyte and edge of tibia. Brightfield images of near-adjacent sections stained with 
Safranin O and Fast Green are shown on the left in (a-e). A: Articular cartilage, G: Growth plate, PS: 
Periosteum and Synovium junction, S: Synovium. Scale bars in all panels indicate 100 µm. 
 
Figure 3. Gdf5-lineage cells are a subset of Pdgfrα-expressing cells in the adult knee.  
(a) Tom+ Gdf5-lineage cells (red) in 14-week-old Gdf5-Cre;Tom mouse knee. Nuclear counterstain is 
shown in blue. A: Articular cartilage, PS: Periosteum and Synovium junction, S: Synovium. Scale bar 
indicates 100 µm. (b) Knee of 11-week-old Pdgfrα-H2BGFP;Gdf5-Cre;Tom mouse showing Tom (red; 
Gdf5-lineage cells) and GFP expression (green; Pdgfrα-expressing cells) (n=3). A: Articular cartilage, 
G: Growth plate, PS: Periosteum and Synovium junction, S: Synovium. Scale bar indicates 100 µm. (c-
h) Freshly isolated cells from knees of Pdgfrα-H2BGFP;Gdf5-Cre;Tom mice (7-10 weeks old) were 
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analysed by flow cytometry. See Supplementary Fig. 1 for gating strategies and FMO controls. (c) 
Representative flow plot showing Tom and GFP expression by single viable cells (n=9, 4 
experiments). (d) Percentage of single viable cells that expressed one or both fluorescent labels 
(mean ± 95% CI, n=9, 4 experiments). (e-h) Phenotypic analysis detecting a range of mesenchymal 
and fibroblast (Gp38, CD90, CD73, CD51, and CD105), haematopoietic (CD45), endothelial (CD31), or 
erythrocyte (Ter-119) markers. (e) Representative flow plots showing expression of Tom and the 
indicated markers within single viable GFP+ cells (n=4-5 for each marker, 4 experiments). (f-h) 
Percentage of single viable cells that express the indicated markers within (f) GFP+Tom+ (Gdf5-
lineage cells), (g) GFP+Tom- (other Pdgfrα-expressing cells), and (h) GFP-Tom- cell populations (mean 
± 95% CI, n=4-5 for each marker, 4 experiments).  
 
Figure 4. Joint-resident SSCs within the Gdf5-lineage form osteophytes.  
(a-c) Adult Gdf5-Cre;Tom mice underwent surgery at 9 weeks to induce DMM in one knee, with 
contralateral knee sham-operated, and BrdU administered from surgery until end of experiment 2 
weeks later. (a) Tom+ Gdf5-lineage cells (red) and BrdU-labelled cells (green) in sham-operated knee 
(n=4). Arrows indicate Tom+ cells along the periosteal surface with incorporated proliferation label. 
(b) Tom+ Gdf5-lineage cells (red) and BrdU-labelled cells (green) in destabilised knee (n=4). Note 
Tom+ cells with incorporated proliferation label throughout the osteophyte. Co-staining for Tom 
(red) with Col2 (green) to reveal cartilage matrix surrounding Tom+ cells is shown on the far right 
(image from different mouse). (c) Percentage of cells in osteophytes that are Tom+ Gdf5-lineage 
cells, and percentage of cells in osteophytes that have incorporated the BrdU proliferation label 
(mean ± 95% CI, n=4). (d,e) Gdf5-Cre;Tom mice underwent DMM surgery at 9-14 weeks and were 
analysed 8 weeks after DMM. (d) Tom+ Gdf5-lineage cells (red) in mature osteophyte (n=7). Arrows 
indicate Tom+ bone lining cells along endosteal surfaces and arrowheads indicate Tom+ osteocytes 
embedded within bone  of the osteophyte. Enlarged image on right shows Tom+ chondrocytes in the 
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cartilage cap. (e) Percentage of cells in osteophytes that are Tom+ Gdf5-lineage cells (mean ± 95% CI, 
n=7), divided into the cartilage cap region, and osteocytes within bone. Fluorescence microscopy 
images in all panels show nuclear counterstain in blue. Dashed white lines in (b,d) indicate boundary 
between osteophyte and edge of tibia. Brightfield images of near-adjacent sections stained with 
Safranin O and Fast Green are shown on the left. Boxed regions indicate areas shown at higher 
magnification on the right. A: Articular cartilage, G: Growth plate, PS: Periosteum and Synovium 
junction, S: Synovium. Scale bars in all panels indicate 100 µm. 
 
Figure 5. Sox9-expressing progenitors give rise to hybrid cells in the early osteophyte.  
(a,b,e) Sox9-CreER;Tom mice were induced with tamoxifen at 7 weeks of age. (a) Tom+ Sox9-traced 
cells (red) in articular cartilage (A), growth plate (G), and scattered within periosteum (P) of knee 
from 9-week-old uninjured mouse (n=3). Boxed region on left indicates area shown at higher 
magnification on the right (different tissue sections are shown). (b) Tom+ Sox9-traced cells (red) 
throughout osteophyte (outlined with dashed white line on far right) at 2 weeks post-DMM (n=3). 
Brightfield image of near-adjacent section stained with Safranin O and Fast Green is shown on the 
left. Boxed region is shown at higher magnification on the far right. A: Articular cartilage, G: growth 
plate. (c,d) Double fluorescence in situ hybridisation in wild-type mouse knees at 1 week (c) or 2 
weeks post-DMM (d) for indicated mRNA targets. Note co-expression of Col2a1 (red) with Col1a1, 
Ocn, Spp1, or Col10a1 (green) in the early osteophyte, and absence of Col1a1 in the tibial growth 
plate (G). Merged and individual channel images of the boxed osteophytes are shown to the right. 
n=3 for each probe combination. (e) Co-detection of Tom with Col2a1 and Col1a1 mRNA in 
osteophyte of Sox9-CreER;Tom mouse (n=3). Individual and merged channel images are shown. Note 
Tom+ Sox9-traced cells (magenta) co-expressing Col2a1 (green) and Col1a1 (red) in outlined area. 
Fluorescence microscopy images in all panels show nuclear counterstain in blue. Scale bars indicate 
100 µm in (a,b) and 200 µm in (c-e). 
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Figure 6. Contribution of Prg4-expressing progenitors to osteophytes.  
(a,b) Prg4-CreER;mTmG mice were induced with tamoxifen at 7 weeks of age, followed by surgery to 
induce DMM in one knee, with contralateral knee sham-operated. Prg4-traced cells were detected 
with anti-GFP antibody (green), and Col1a1 or Col2a1 mRNA expression by fluorescence in situ 
hybridisation (red). (a) GFP+ Prg4-traced cells at articular surface and in synovial lining in control 
sham-operated knee (n=3). Note membrane localisation of GFP, indicating successful mTmG 
conversion. (b) GFP+ Prg4-traced cells at 2 weeks post-DMM. Note expansion in synovium but 
minimal contribution to hybrid cells that express Col1a1 and Col2a1 in the early osteophyte (n=3). 
Boxes indicate magnified images to the right, shown as merged and individual channels. Arrowheads 
indicate rare Prg4-traced cells expressing Col2a1. (c-h) Prg4-CreER;Tom mice were induced with 
tamoxifen at 8 weeks of age. (c) Tom+ Prg4-traced cells (red) in synovial lining and superficial zone of 
articular cartilage in 10-week-old uninjured mouse (n=7, 3 experiments). Green: Col2 
immunostaining (n=3). (d) Tom+ Prg4-traced cells (red) in osteophyte at 2 weeks post-DMM (n=8, 2 
experiments). Note Tom+ cells in Col2+ (green) cartilage matrix and overlying synovial tissue. (e) 
Percentage of cells that expressed Tom at 2 weeks post-DMM in Col2+ cartilage matrix or Col2- 
tissue of the osteophyte (mean ± 95% CI, n=8, 2 experiments). (f) Tom+ Prg4-traced cells (red) in 
Col10+ (green) hypertrophic cartilage of osteophyte 2 weeks post-DMM, indicated by arrows (n=4). 
(g) Tom+ Prg4-traced cells (red) in osteophyte at 8 weeks post-DMM (n=7, 2 experiments). Green: 
Col2 immunostaining. (h) Percentage of cells that expressed Tom at 8 weeks post-DMM in Col2+ 
cartilage matrix or Col2- tissue of the osteophyte cap, or among osteocytes in the osteophyte bone 
(mean ± 95% CI, n=7, 2 experiments). Fluorescence microscopy images show nuclear counterstain in 
blue. Brightfield images of Safranin-O-stained near-adjacent sections are shown on the left in (d,g). 
Dashed white lines indicate boundary between osteophyte and edge of tibia in (d,f,g). A: Articular 
cartilage, G: Growth plate, PS: Periosteum and Synovium junction, S: Synovium. Scale bars indicate 
200 µm in (a,b) and 100 µm in (c,d,f,g). 
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Figure 7. Proposed model of osteophyte formation in OA.  
Our data show that Pdgfrα+ Gdf5-lineage progenitors, which in the normal joint are present at the 
junction of periosteum and synovium near the articular cartilage, are activated in OA to form both 
the cartilage and bone of the osteophyte. They include Prg4-expressing progenitors (orange) 
residing in synovial lining and Sox9-expressing progenitors (green) in the underlying periosteum. 
During the early stage of osteophyte formation, Sox9-expressing progenitors in periosteum give rise 
to hybrid skeletal cells that form a transient cartilage template which is remodelled to bone. Progeny 
of Prg4-expressing progenitors are recruited to the forming osteophyte and supply chondrocytes to 
the cartilage, but they make negligible contributions to osteoblast-lineage cells that form the bone. 
A: Articular cartilage, M: meniscus.  
 
KEY MESSAGES 
What is already known about this subject? 
Osteophytes are a key feature of osteoarthritis. Several skeletal stem and progenitor cell populations 
have been identified; however, their contribution to osteophyte formation remains unexplored. 
What does this study add? 
This study shows that descendants of the Gdf5-expressing cells of the embryonic joint interzone 
form osteophytes in osteoarthritis, and reveals contributions of two distinct progenitor cell 
populations residing in periosteum and synovium.  
How might this impact on clinical practice or future developments? 
This study defines the progenitor cell subsets forming the osteophytes, which could be targeted as 
part of disease modification strategies for treatment of osteoarthritis. 
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Supplementary Figure 1. Flow cytometry analysis of adult Gdf5-lineage and Pdgfrα-expressing 
cells. (a) Gating strategy to identify GFP-Tom-, GFP+Tom- and GFP+Tom+ cells within single live cells 
freshly isolated from knees of adult Pdgfrα-H2BGFP; Gdf5-Cre; Tom mice (n=9, 3 experiments). 
Erythrocytes and debris were gated out based on Forward and Side Scatter profile. Doublets and 
aggregates were excluded based on Forward Scatter parameters. Dead cells were excluded based on 
viability dye staining. (b) Gates for detection of cell surface markers were set using fluorescence-
minus-one (FMO) controls. (c) Representative flow cytometry plots for the analysis of cell surface 
markers (n=4-5 for each marker, pooled data from 3 experiments). 
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Supplementary Figure 2. Hybrid cells in early osteophytes of Col2-CreER animals. Detection of 
Col1a1 (a) and Col2a1 (b) in early osteophyte (arrow) at 1 week post-DMM by fluorescence in situ 
hybridisations on adjacent sections of knee from 9-week-old Col2-CreER; mTmG mouse (n=2). Note 
also expression of Col2a1 but not Col1a1 in chondrocytes within the tibial growth plate (G). Nuclear 
counterstain is shown in blue. A: Articular cartilage. Scale bar indicates 100 µm.   
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Supplementary Table 1. Transgenic mouse lines. 
Short name Full name Source Ref. 
Pdgfrα-H2BGFP B6.129S4-Pdgfratm11(EGFP)Sor/J JAX, stock no. 7669 1 
Nes-GFP Tg(Nes-EGFP)33Enik G Enikolopov (CSHL) 2 
Col2-CreER FVB-Tg(Col2a1-cre/ERT)KA3Smac/J JAX, stock no. 6774 3 
Pdgfrα-CreER B6N.Cg-Tg(Pdgfra-cre/ERT)467Dbe/J JAX, stock no. 18280 4 
Nes-CreER Tg(Nes-cre/ERT2)1Fsh G Fishell (New York) 5 
LepR-Cre Leprtm3(cre)Mgmj L Heisler (Aberdeen) 6 
Grem1-CreER B6.Cg-Tg(Grem1-cre/ERT)3Tcw/J JAX, stock no. 27039 7 
Gdf5-Cre Tg(Gdf5-cre-ALPP)1Kng D Kingsley (Stanford) 8 
Prg4-CreER STOCK Prg4tm1(GFP/cre/ERT2)Abl/J A Lassar (Harvard) 9 
Sox9-CreER Sox9tm1(cre/ERT2)Haak H Akiyama (Kyoto) 10 
TdTomato B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J JAX, stock no. 6774 11 
TdTomato  
(for Sox9-tracing) 
B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J JAX, stock no. 7905 
11 
Confetti STOCK Gt(ROSA)26Sortm1(CAG-Brainbow2.1)Cle/J JAX, stock no. 13731 12 
mTmG B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo/J 
JAX, stock no. 7676 13 
 
 
Supplementary Table 2. Tamoxifen administration and age at surgery. 
Short name Age at start Dose, route and frequency of tamoxifen Age at surgery 
Col2-CreER;Tom 2 w 75 mg/kg i.p. daily for 5 days 13-14 weeks  
Pdgfrα-CreER; 
Confetti 
11-12 w 200 mg/kg via oral gavage daily for 5 days, 
and 9 days later for a further 5 days 
15-16 weeks  
(6 days after last Tam) 
Nes-CreER;Tom 1 d 143 mg/kg via oral gavage to mother on 
day 1, 3, and 5 after delivery 
10 weeks  
Grem1-CreER;Tom 7 w 2 mg i.p. daily for 3 days 8 weeks  
(4 days after last Tam) 
Sox9-CreER;Tom 7 w 2 mg i.p. daily for 3 days 8 weeks  
(4 days after last Tam) 
Prg4-CreER;mTmG 7 w 2 mg i.p. every other day for 10 days 9 weeks  
(4 days after last Tam) 
Prg4-CreER;Tom 8 w 75 mg/kg i.p. daily for 5 days, and 2 days 
later for a further 5 days 
10 weeks  
(4 days after last Tam) 
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Supplementary Table 3. Antibodies for immunohistochemistry. 
Antibody Clone Manufacturer Cat. No. Conjugation 
Collagen type II (Col2) polyclonal Abcam  ab21291 unconjugated 
Collagen type II (Col2) polyclonal Abcam ab34712 unconjugated 
Collagen type II (Col2) 6B3 Merck MAB8887 unconjugated 
Collagen type X (Col10) X53 Quartett Berlin 1-CO097-05 unconjugated 
BrdU BU1/75 (ICR1) Abcam ab6326 unconjugated 
mCherry (detects Tom) polyclonal Abcam ab0081 unconjugated 
mCherry (detects Tom) polyclonal Novus Biologicals NBP2-25158SS unconjugated 
RFP (detects Tom) polyclonal Origene AB1140-100 unconjugated 
GFP polyclonal Abcam ab6556 unconjugated 
GFP polyclonal Abcam Ab13970 unconjugated 
GFP polyclonal Torrey Pines TP401 unconjugated 
Goat anti-chicken  polyclonal  Abcam  Ab150169 Alexa Fluor 488 
Goat-anti-chicken polyclonal Abcam Ab175477 Alexa Fluor 568 
Donkey anti-goat  polyclonal Abcam Ab150129 Alexa Fluor 488 
Donkey anti-goat polyclonal Thermo Fisher A-21432 Alexa Fluor 555 
Donkey anti-goat  polyclonal Abcam Ab150132 Alexa Fluor 594 
Donkey anti-goat polyclonal Abcam Ab150131 Alexa Fluor 647 
Donkey anti-mouse polyclonal Thermo Fisher A-21202 Alexa Fluor 488 
Donkey anti-rabbit polyclonal Abcam Ab150073 Alexa Fluor 488 
Donkey anti-rabbit  polyclonal Abcam Ab150076 Alexa Fluor 594 
Donkey anti-rabbit polyclonal Abcam Ab150075 Alexa Fluor 647 
Goat-anti-rabbit polyclonal Thermo Fisher  A-11011 Alexa Fluor 568 
 
 
Supplementary Table 4. Antibodies for flow cytometry. 
Antibody Clone Manufacturer Cat. No. Conjugation 
CD73 TY/11.8 eBioscience 48-0731-82 eF450 
CD90 OX-7 BD Biosciences 563770 BV421 
CD105 MJ7/18 BD Biosciences 562760 BV421 
CD51 RMV-7 BD Biosciences 740755 BV711 
CD45 30-F11 BD Biosciences 564279 BUV395 
CD31 390 BD Biosciences 740239 BUV395 
Ter-119 TER-119 BD Biosciences 563827 BUV395 
GP38 8.1.1 Biolegend 127410 APC 
Viability Dye - eBioscience 65-0865-18 eF780 
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